1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 4,019.62 | 3,641.34 | 2,989.20 | 2,553.87 |
| Total Income | 508.93 | 1,959.58 | 1,582.26 | 1,369.66 |
| Profit After Tax | 267.57 | 70.68 | -4.88 | -40.54 |
| EBITDA | 78.73 | 309.40 | 190.45 | 168.82 |
| NET Worth | 3,889.99 | 2,752.52 | 2,681.02 | 2,629.52 |
| Reserves and Surplus | 2,299.84 | 1,150.74 | 1,135.71 | 1,073.12 |
| Total Borrowing | 793.42 | 1,729.46 | 813.10 | 556.54 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Fabtech Technologies Ltd. | Mainboard | ₹230.30 Cr | ₹191 | 13.32 | ₹182.40 | -4.50% | ₹149.73 (+0.27%) |
| Q-Line Biotech Ltd. | SME | ₹214.48 Cr | ₹343 | 20.82 | ₹474.60 | +38.37% | ₹505.75 (+1.37%) |
| Earkart Ltd. | SME | ₹49.26 Cr | ₹135 | 20.48 | ₹142.25 | +5.37% | ₹159.00 (-0.62%) |
| Galaxy Medicare Ltd. | SME | ₹22.31 Cr | ₹54 | 19.01 | ₹51.30 | -5.00% | ₹17.60 (+0.00%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by: | 696.39 |
| 2 | The wholly-owned Subsidiaries, namely, Translumina Therapeutics Private Limited (“Translumina Therapeutics”), Transhealth Private Limited (“Transhealth”) ”) and HaleMed Medical Private Limited; and | 125.40 |
| 3 | The step-down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd. | 571.00 |
| 4 | General corporate purposes |
About Integris Medtech IPO
Incorporated in 2008, Integris Medtech Ltd is a diversified India-based global medical products and laboratory solutions company. The company develops, manufactures, commercialises, and sells a broad portfolio of medical devices and solutions spanning cardiovascular devices, clinical diagnostics, and scientific laboratory solutions. Integris Medtech operates manufacturing facilities in India, Germany, and the Netherlands, supplying products to more than 65 international markets across India, Europe, and Southeast Asia. Its customer base includes over 9,500 laboratories and 2,000 hospitals and cathlabs, supported by a portfolio exceeding 22,000 SKUs across more than 200 brands in laboratory and cardiovascular segments. The company’s business is structured into two core divisions: Cardiovascular Devices – encompassing drug-eluting stents, drug-coated balloons, complex coronary intervention products, and vascular access solutions. Laboratory Solutions – covering clinical, research, and industrial laboratory equipment, reagents, and consumables, along with services such as instrument installation, maintenance, and calibration through its BioCal™ brand. Integris Medtech supports laborat
Contact Details
Integris Medtech Ltd. Address1 st FloorMetro Tower LSCM.O.R Land, New Rajinder NagarNorth Delhi, New Delhi, 110060+91 120 4531422investors@integrismedtech.comVisit Website